Lakewood-Amedex Biotherapeutics direct listed on Nasdaq under LABT on April 23, 2026, sparking intense retail hype and viral interest on platforms like StockTwits. Shares opened around $8, surged intraday toward $9–14 levels with heavy volume, closed at $8.65 (+8%), then fell 15% to $7.35 on April 24 amid over 5 million shares traded. By April 27, the stock opened at $5.75 and closed at $5.64 (down ~23% from April 24 close, aligning with the reported -21.22% move). This reversal reflects fading momentum in a pre-revenue clinical-stage biotech with no new clinical data, earnings, or positive announcements. The company’s lead Bisphosphocin candidate (Nu-3 gel for infected diabetic foot ulcers) is advancing toward a Phase 2a trial later in 2026, but the direct listing raised no new capital. Reports highlighted an impending cash crunch and high likelihood of future equity raises that would dilute shareholders, prompting selling from registered resale shares (noted in the April 23 424B4 filing covering ~4.7 million shares) and profit-taking after the initial pop. No specific negative news (e.g., trial results or regulatory issues) emerged; the move is a classic post-hype correction in a speculative micro-cap name.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.